Merck KGaA Valuation
| MKKGY Stock | USD 30.30 0.60 2.02% |
At this time, the firm appears to be undervalued. Merck KGaA ADR secures a last-minute Real Value of $31.75 per share. The latest price of the firm is $30.3. Our model forecasts the value of Merck KGaA ADR from analyzing the firm fundamentals such as Return On Equity of 0.14, current valuation of 92.22 B, and Profit Margin of 0.16 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Merck KGaA's price fluctuation is very steady at this time. Calculation of the real value of Merck KGaA ADR is based on 3 months time horizon. Increasing Merck KGaA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Merck KGaA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Merck Pink Sheet. However, Merck KGaA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.3 | Real 31.75 | Hype 30.3 | Naive 30.84 |
The intrinsic value of Merck KGaA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Merck KGaA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Merck KGaA ADR helps investors to forecast how Merck pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Merck KGaA more accurately as focusing exclusively on Merck KGaA's fundamentals will not take into account other important factors: Merck KGaA Total Value Analysis
Merck KGaA ADR is now forecasted to have takeover price of 92.22 B with market capitalization of 88.17 B, debt of 7.93 B, and cash on hands of 1.71 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Merck KGaA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
92.22 B | 88.17 B | 7.93 B | 1.71 B |
Merck KGaA Investor Information
The book value of the company was now reported as 12.98. The company last dividend was issued on the 25th of April 2022. Merck KGaA ADR had 1666:1000 split on the 15th of August 2017. Based on the key measurements obtained from Merck KGaA's financial statements, Merck KGaA ADR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Merck KGaA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Merck KGaA has an asset utilization ratio of 43.4 percent. This suggests that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Merck KGaA ADR is more efficient with each dollar of assets it utilizes for everyday operations.Merck KGaA Ownership Allocation
Merck KGaA ADR maintains a total of 2.17 Billion outstanding shares. Roughly 99.97 % of Merck KGaA outstanding shares are held by general public with 0.03 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Merck KGaA Profitability Analysis
The company reported the revenue of 19.69 B. Net Income was 3.06 B with profit before overhead, payroll, taxes, and interest of 12.36 B.About Merck KGaA Valuation
Our relative valuation model uses a comparative analysis of Merck KGaA. We calculate exposure to Merck KGaA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Merck KGaA's related companies.MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kgaa operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 62770 people.
8 Steps to conduct Merck KGaA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Merck KGaA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Merck KGaA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Merck KGaA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Merck KGaA's revenue streams: Identify Merck KGaA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Merck KGaA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Merck KGaA's growth potential: Evaluate Merck KGaA's management, business model, and growth potential.
- Determine Merck KGaA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Merck KGaA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Merck KGaA Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.2 B | |
| Quarterly Earnings Growth Y O Y | 0.211 | |
| Forward Price Earnings | 16.3934 | |
| Retained Earnings | 15.1 B |
Additional Tools for Merck Pink Sheet Analysis
When running Merck KGaA's price analysis, check to measure Merck KGaA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck KGaA is operating at the current time. Most of Merck KGaA's value examination focuses on studying past and present price action to predict the probability of Merck KGaA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck KGaA's price. Additionally, you may evaluate how the addition of Merck KGaA to your portfolios can decrease your overall portfolio volatility.